BioInvent International AB (publ) (LON:0H22)
23.73
+0.43 (1.82%)
At close: Feb 21, 2025
LON:0H22 Revenue
BioInvent International AB had revenue of 12.76M SEK in the quarter ending September 30, 2024, a decrease of -52.37%. This brings the company's revenue in the last twelve months to 38.64M, down -49.68% year-over-year. In the year 2023, BioInvent International AB had annual revenue of 71.46M, down -78.09%.
Revenue (ttm)
38.64M SEK
Revenue Growth
-49.68%
P/S Ratio
n/a
Revenue / Employee
348.07K SEK
Employees
111
Market Cap
115.42M GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
Dec 31, 2019 | 93.74M | 55.19M | 143.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Genus | 668.80M |